THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...
Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put ...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.
Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...
The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results